RSH-7

CAS No. 2764609-97-2

RSH-7( —— )

Catalog No. M36539 CAS No. 2764609-97-2

RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 147 In Stock
5MG 250 In Stock
10MG 407 In Stock
25MG 748 In Stock
50MG 1086 In Stock
100MG 1458 In Stock
500MG 2907 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    RSH-7
  • Note
    Research use only, not for human use.
  • Brief Description
    RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.
  • Description
    RSH-7 is a potent BTK and FLT3 inhibitor with IC50s of 47, 12 nM, respectively. RSH-7 induces apoptosis and shows antiproliferative activities. RSH-7 inhibits BTK and FLT3 signaling and shows anti-tumor activity.
  • In Vitro
    RSH-7 (1-1000 nM; 72 h) shows antiproliferative activities with IC50s of 17, 3, 11, 930 nM for Jeko-1, MV-4-11, Molt4, K562 cells, respectively.RSH-7 (30, 150, 750 nM; 72 h) decreases the expression of p-BTK (TYR223), p-PLCγ(Tyr1217), p-FLT3 (Tyr589), p-STAT5 (TYR694) in a dose-dependent manner.RSH-7 (30, 150, 750 nM; 72 h) induces apoptosis and increases the expression of BAX, p53, cleaved caspase 3 in a dose dependen manner in jeko-1 cells..Cell Viability Assay Cell Line:Jeko-1, MV-4-11, Molt4, K562 cells Concentration:1-1000 nM Incubation Time:72 h Result:Showed antiproliferative activities with IC50s of 17, 3, 11, 930 nM for Jeko-1, MV-4-11, Molt4, K562 cells, respectively.Western Blot Analysis Cell Line:jeko-1 cells Concentration:30, 150, 750 nM Incubation Time:72 h Result:Reduced both BTK, PLCγ2, FLT3 and STAT5 phosphorylation in a dose-dependent manner.Apoptosis Analysis Cell Line:jeko-1 cellsConcentration:30, 150, 750 nM Incubation Time:72 h Result:Dose-dependently induced cell apoptosis and upregulated the expression of pro-apoptotic protein BAX, p53, cleaved caspase 3.
  • In Vivo
    RSH-7 (25, 50 mg/kg; i.p.; daily for 16 days) shows anti-tumor activity with significantly and dose-dependently suppresses the tumor growth in mouse.Animal Model:Female NOD/SCID mice (jeko-1 cell-inoculated xenograft NOD/SCID mice models)Dosage:25, 50 mg/kg Administration:I.p.; daily for 16 days Result:Suppressed tumor growth in a dose-dependent manner, with tumor growth inhibition (TGI) values of 66.95% and 79.78% at doses of 25 and 50 mg/kg,Animal Model:Female NOD/SCID mice (MV4-11 cell-inoculated xenograft NOD/SCID mice models)Dosage:10, 20 mg/kg Administration:I.p.; daily for 21 days Result:Significantly and dose-dependently suppressed the tumor growth with the TGI rates of 74.23% and 94.84% at the dosage of 10 and 20 mg/kg, respectively.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | FLT | BTK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2764609-97-2
  • Formula Weight
    436.49
  • Molecular Formula
    C22H25FN8O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (190.91 mM; Ultrasonic )
  • SMILES
    N(C1=C(C(NN)=O)C=CC=C1)C2=NC(NC3=CC=C(C=C3)N4CCN(C)CC4)=NC=C2F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ran F, et al. Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114913.?
molnova catalog
related products
  • L-Cystathionine

    L-Cystathionine is a key nonprotein amino acid related to metabolic conditions of sulfur-containing amino acids.

  • ABT-510 acetate

    ABT-510 acetate is an endogenous anti-angiogenic TSP peptide inhibitor, a thrombospondin analog, with anti-inflammatory, anti-cancer and anti-angiogenic activity that induces apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.

  • AAPK-25

    AAPK-25, a potent and selective dual inhibitor of Aurora/PLK, causes mitotic delay and cell arrest in prometaphase, via phosphorylation of the biomarker histone H3Ser10, followed by a surge in apoptosis.